From: Three-years outcomes of diabetic patients treated with coronary bioresorbable scaffolds
All patients (n = 657) | Patients with diabetes (n = 138) | Patients without diabetes (n = 519) | P-value | |
---|---|---|---|---|
Age (years) | 63 ± 12 | 65 ± 11 | 62 ± 12 | 0.015 |
Male | 519/657 (79.0%) | 107/138 (77.5%) | 412/519 (79.4%) | 0.722 |
Hypertension | 478/657 (72.8%) | 117/138 (84.8%) | 361/519 (69.6%) | < 0.001 |
Smoking | 273/657 (41.6%) | 48/138 (34.8%) | 225/519 (43.3%) | 0.086 |
Family History | 138/657 (21.0%) | 21/138 (15.2%) | 117/519 (22.5%) | 0.078 |
Hyperlipidemia | 268/657 (40.8%) | 76/138 (55.1%) | 192/519 (37.0%) | < 0.001 |
Prior CABG | 14/657 (2.1%) | 5/138 (3.6%) | 9/519 (1.7%) | 0.186 |
Prior PCI | 181/657 (27.5%) | 48/138 (34.8%) | 133/519 (25.6%) | 0.042 |
Prior stroke/TIA | 27/657 (4.1%) | 11/138 (8.0%) | 16/519 (3.1%) | 0.020 |
eGFR (ml/min) | 83 ± 23 | 76 ± 25 | 84 ± 22 | < 0.001 |
LVEF (%) | 52 ± 8 | 53 ± 7 | 52 ± 9 | 0.590 |
Silent/stable angina | 219/657 (33.3%) | 56/138 (40.6%) | 163/519 (31.4%) | 0.054 |
Unstable Angina | 78/657 (11.9%) | 20/138 (14.5%) | 58/519 (11.1%) | 0.356 |
NSTEMI | 191/657 (29.1%) | 33/138 (23.9%) | 158/519 (30.4%) | 0.163 |
STEMI | 166/657 (25.3%) | 28/138 (20.3%) | 138/519 (26.6%) | 0.161 |
Lesion characteristics | ||||
LAD treated with BRS | 301/657 (45.8%) | 68/138 (49.3%) | 233/519 (44.9%) | 0.411 |
LCX treated with BRS | 161/657 (24.4%) | 36/138(26.1%) | 125/519(24.1%) | 0.708 |
RCA treated with BRS | 194/657 (29.7%) | 34/138 (24.6%) | 160/519 (30.8%) | 0.190 |
Graft treated with BRS | 1/657 (0.2%) | 0/138 (0%) | 1/519 (0.2%) | 1 |
Ostial lesion | 53/657 (8.1%) | 10/138 (7.2%) | 43/519 (8.3%) | 0.824 |
CTO | 11/657(1.7%) | 2/138 (1.4%) | 15/519 (2.9%) | 0.546 |
Bifurcation | 82/657(12.5%) | 13/138(9.4%) | 69/519(13.3%) | 0.281 |
At least one lesion type B2 or C | 297/657 (45.2%) | 62/138 (44.9%) | 235/519 (45.3%) | 0.982 |
Procedural characteristics | ||||
Number of vessels treated with BVS | 1.2 ± 0.4 | 1.2 ± 0.5 | 1.1 ± 0.4 | 0.095 |
Number of BRS per patient | 1.4 ± 0.8 | 1.5 ± 0.9 | 1.4 ± 0.8 | 0.181 |
vHybrid BRS + DES | 330/657(50.2%) | 56/138(40.6%) | 274/519(52.8%) | 0.014 |
Predilatation | 653/657(99.4%) | 136/138(98.6%) | 517/519(99.6%) | 0.196 |
Diameter predilatation ballon (mm) | 2.80 ± 0.37 | 2.83 ± 0.36 | 2.80 ± 0.37 | 0.367 |
Minimum stent diameter per patient (mm) | 2.97 ± 0.38 | 2.96 ± 0.36 | 2.98 ± 0.38 | 0.572 |
Total implanted length per patient (mm) | 27.5 ± 18.9 | 29.0 ± 19.4 | 27.2 ± 18.8 | 0.324 |
Postdilatation | 306/657(46.6%) | 71/138(51.4%) | 235/519(45.3%) | 0.232 |
Preprocedural RVD, mm | 2.93 ± 0.67 | 2.91 ± 0.77 | 2.94 ± 0.65 | 0.728 |
Preprocedural MLD, mm | 0.61 ± 0.51 | 0.71 ± 0.41 | 0.58 ± 0.54 | 0.026 |
% stenosis per lesion | 78.2 ± 17.9 | 74.6 ± 13.6 | 79.4 ± 18.8 | 0.014 |
Angiographic Outcome | ||||
Postprocedural RVD, mm | 3.0 ± 0.5 | 3.0 ± 0.4 | 3.0 ± 0.5 | 0.760 |
vPostprocedural MLD, mm | 2.5 ± 0.5 | 2.5 ± 0.5 | 2.5 ± 0.5 | 0.135 |
Residual stenosis per lesion (%) | 14.5 ± 10.8 | 16.7 ± 13.2 | 13.7 ± 9.9 | 0.018 |
MLD/nominal BRS diameter | 0.84 ± 0.13 | 0.82 ± 0.16 | 0.85 ± 0.13 | 0.101 |
Lumen Gain, mm | 1.63 ± 0.62 | 1.61 ± 0.61 | 1.68 ± 0.56 | 0.382 |
Optimal implantation technique | 311/657 (47.3%) | 74/138 (53.6%) | 237/519 (45.7%) | 0.117 |
Overlap | 74/657 (11.3%) | 12/138 (8.7%) | 62/519 (11.9%) | 0.357 |
Clopidogrel | 200/657 (30.4%) | 51/138 (37.0%) | 149/519 (28.7%) | 0.077 |
Prasugrel | 324/657 (49.3%) | 67/138 (48.6%) | 257/519 (49.5%) | 0.915 |
Ticagrelor | 132/657 (20.1%) | 19/138 (13.8%) | 113/519 (21.8%) | 0.076 |